Copyright 2009 Medical News Today Latest Pancreatic Cancer News From Medical News Today. http://www.medicalnewstoday.com/sections/pancreatic-cancer/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Wed, 25 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/172019.php http://www.medicalnewstoday.com/articles/172019.php "Screening for Barrett's esophagus in asymptomatic women" Barrett's esophagus is a condition where the lining of the esophagus changes due to chronic inflammation, generally from gastroesophageal reflux disease (GERD). Barrett's esophagus is important to recognize as it may increase the risk of developing esophageal cancer. GastroIntestinal / Gastroenterology Sun, 22 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/171738.php http://www.medicalnewstoday.com/articles/171738.php Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO). Radiology / Nuclear Medicine Sat, 21 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171770.php http://www.medicalnewstoday.com/articles/171770.php Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology Biology Physics, the official journal of the American Society for Radiation Oncology (ASTRO). Pancreatic Cancer Fri, 20 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/171677.php http://www.medicalnewstoday.com/articles/171677.php There are minimal data assessing the relationship between diabetes and gallbladder, biliary and pancreatic cancer. Recent small studies have suggested an elevated risk of pancreatic cancer only in patients with diabetes mellitus (DM). A research article published on November 14, 2009 in the World Journal of Gastroenterology addresses this question. The research team, lead by Dr. Diabetes Sun, 08 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/170168.php http://www.medicalnewstoday.com/articles/170168.php Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma. Pancreatic Cancer Fri, 06 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/169999.php http://www.medicalnewstoday.com/articles/169999.php The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has renewed the contract to continue studying asthma in children living in lower-income, inner-city environments. Respiratory / Asthma Tue, 03 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169646.php http://www.medicalnewstoday.com/articles/169646.php Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. Pancreatic Cancer Tue, 03 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169589.php http://www.medicalnewstoday.com/articles/169589.php Study results: MIT cancer biologists have identified a subpopulation of cells that can give rise to pancreatic cancer. They also found that tumors can form in other, more mature pancreatic cell types, but only when they are injured or inflamed, suggesting that pancreatic cancer can arise from different types of cells depending on the circumstances. Pancreatic Cancer Mon, 02 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169468.php http://www.medicalnewstoday.com/articles/169468.php A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor. The results contradict a previous study in 2008 that suggested a link between pancreatic cancer and previous hepatitis B infection. Hepatitis B is an inflammation of the liver caused by a viral infection. Pancreatic Cancer Sun, 25 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168546.php http://www.medicalnewstoday.com/articles/168546.php Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers. Cancer / Oncology Fri, 23 Oct 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/168525.php http://www.medicalnewstoday.com/articles/168525.php It is very difficult to predict whether a cancer drug will help an individual patient: only around one third of drugs will work directly in a given patient. Researchers at the Heinz Nixdorf Chair for Medical Electronics at the Technische Universitaet Muenchen (TUM) have developed a new test process for cancer drugs. With the help of microchips, they can establish in the laboratory whether a patient's tumor cells will react to a given drug. Cancer / Oncology Thu, 22 Oct 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/168346.php http://www.medicalnewstoday.com/articles/168346.php Cancer cells fueled by the mutant KRAS oncogene, which makes them notoriously difficult to treat, can be killed by blocking a more vulnerable genetic partner of KRAS, report scientists at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. Pancreatic Cancer Tue, 20 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/167894.php http://www.medicalnewstoday.com/articles/167894.php Repligen Corporation (Nasdaq: RGEN) reported that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging (MRI) of the pancreas. The study is designed to assess the sensitivity and specificity of RG1068 in conjunction with MRI for the detection of pancreatic duct abnormalities compared to MRI alone. Pancreatic Cancer Thu, 15 Oct 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/167415.php http://www.medicalnewstoday.com/articles/167415.php Epeius Biotechnologies confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Pancreatic Cancer Wed, 14 Oct 2009 19:00:00 PST http://www.medicalnewstoday.com/articles/167343.php http://www.medicalnewstoday.com/articles/167343.php Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy. They presented their findings at the 95th annual Clinical Congress of the American College of Surgeons. Pancreatic Cancer Wed, 14 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/167241.php http://www.medicalnewstoday.com/articles/167241.php Researchers at the University of California Los Angeles (UCLA) have found that a second molecular pathway may need to be blocked to prevent malignant cells from creating new blood vessels [angiogenesis]. A study of patients with pancreatic cancer showed that CXCL5 may be a key molecule in the angiogenesis switch the point at which cells stop being normal and start producing blood vessels that feed malignancy. Pancreatic Cancer Mon, 05 Oct 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/166213.php http://www.medicalnewstoday.com/articles/166213.php SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced the discontinuation of the investigational treatments under its randomized, placebo-controlled, double-blind Phase 2 trial that is evaluating RP101 -- a nucleoside analog known as BvdU -- for the treatment of late-stage pancreatic cancer. Pancreatic Cancer Fri, 02 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/165914.php http://www.medicalnewstoday.com/articles/165914.php ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today results from its pilot study evaluating the cancer detection abilities of one of its lead monoclonal antibody product candidates, ICT-109. Pancreatic Cancer Fri, 25 Sep 2009 07:00:00 PST http://www.medicalnewstoday.com/articles/165293.php http://www.medicalnewstoday.com/articles/165293.php For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease. Dr Davide Melisi told Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], in Berlin, that resistance to chemotherapy was the greatest challenge to treating pancreatic cancer. Pancreatic Cancer Wed, 23 Sep 2009 07:00:00 PST http://www.medicalnewstoday.com/articles/164955.php http://www.medicalnewstoday.com/articles/164955.php Patients with soft-tissue sarcomas at high risk of spreading were 30% more likely to be alive and cancer free almost three years after starting treatment if their tumours were heated at the time they received chemotherapy, according to new research. The finding bolsters the case for intensifying exploration of the strategy in other types of cancer. Cancer / Oncology Tue, 22 Sep 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/164686.php http://www.medicalnewstoday.com/articles/164686.php The American Gastroenterological Association (AGA) Foundation for Digestive Health and Nutrition (FDHN) announced that the family of the late businessman and photographer, Bernard Lee Schwartz, has honored his memory by establishing a new three-year Research Scholar Award for pancreatic cancer research. Pancreatic Cancer Sun, 20 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/164485.php http://www.medicalnewstoday.com/articles/164485.php Neogenix Oncology, Inc. (Neogenix) announced that NPC-1C, the company's first IND (Investigational New Drug Application) was granted permission by the Food and Drug Administration (FDA) for the company to begin a Phase I trial. NPC-1C is derived from a colorectal cancer vaccine that had previously demonstrated safety and clinical activity in prior human studies. NPC-1C is a novel, monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer. Pancreatic Cancer Sat, 19 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/164453.php http://www.medicalnewstoday.com/articles/164453.php Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour. Pancreatic stellate cells (PSC) are the principal effector cells in pancreatic fibrosis. They are activated by profibrogenic mediators, which include, for example, cytokines and ethanol metabolites. Pancreatic Cancer Thu, 17 Sep 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/164296.php http://www.medicalnewstoday.com/articles/164296.php Intraductal papillary mucinous neoplasms (IPMN) can evolve through all biological stages, from slight dysplasia to carcinoma. As one of the few surgically curable pancreatic tumors, accurate preoperative prediction of malignancy remains one of the major issues in the optimal treatment of IPMNs, and it also influences the outcome of the resection. Pancreatic Cancer Tue, 15 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/163857.php http://www.medicalnewstoday.com/articles/163857.php The biopharmaceutical company Antisense Pharma GmbH has announced that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug trabedersen in the treatment of pancreatic carcinoma. Trabedersen has already been granted orphan drug designation by both authorities in the treatment of high-grade gliomas in 2002. Pancreatic Cancer